Piramal Pharma Limited has completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based contract development and manufacturing organisation (CDMO) specialising in vaccines and biologics.

Tagomics Ltd., a precision medicine company, has launched LiquiPath™, a cross-species, multi-organ liquid pathology platform designed for non-invasive drug safety monitoring. The platform is intended for use

Photys Therapeutics, Inc. (“Photys”), a proximity-based therapeutics company, and Polymed Biopharmaceuticals, Inc. (“Polymed”), a global biotech company focused on creating best-in-class PROTACs

Aurisco Pharmaceutical has announced that its manufacturing site in Yangzhou, China, has successfully completed a US Food and Drug Administration (FDA) inspection, making it the first generic oligonucleotide active pharmaceutical ingredient (API) manufacturer to pass a US FDA inspection, according to the company.

Sentynl Therapeutics, a US-based biopharmaceutical company and subsidiary of Zydus Lifesciences, and Mereo BioPharma Group have entered into an option and licence agreement covering the US commercial

SOLIZE PARTNERS Corporation and Dassault Systèmes Japan have entered into a Consulting and System Integration Partner Programme agreement to help manufacturers accelerate digital transformation, improve operational efficiency and support innovation.

Evotec has entered into a strategic research and development collaboration with Odyssey Therapeutics to discover new small molecule treatments for autoimmune and inflammatory diseases.

SystImmune has dosed the first patient in its global Phase 3 BrenDeLL-Lung01 trial, which is evaluating the investigational antibody-drug conjugate (ADC) BL-M14D1 in combination with atezolizumab as a first-line treatment for patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC).

Phylo has entered into a collaboration with Chugai Pharmaceutical to deploy Biomni Lab, its agentic AI platform for biomedical research, across Chugai’s drug discovery programmes.

Fresenius Kabi, an operating company of Fresenius, has announced that the U.S. Food and Drug Administration (FDA) has approved a rituximab biosimilar developed by Dr. Reddy's Laboratories (DRL).